← Older revision
Revision as of 04:11, 21 October 2012
(3 intermediate revisions by one user not shown)
Line 1:
Line 1:
__NOTOC__
__NOTOC__
{{Diastolic dysfunction}}
{{Diastolic dysfunction}}
−
{{CMG}}
+
{{CMG}}
; '''Associate Editor(s)-in-Chief:''' [[User: Shankar Kumar |Shankar Kumar, M.B.B.S.]] [mailto:kumarshankar@wikidoc.org]
==Overview==
==Overview==
+
The initial laboratory tests in diastolic dysfunction or failure include [[complete blood count]], [[urinalysis]], [[Electrolytes|serum electrolytes]], [[blood urea nitrogen]], [[serum creatinine]], [[fasting blood glucose]] ([[glycohemoglobin]]), [[lipid]] profile, [[liver function tests]], and [[thyroid-stimulating hormone]]. The measurement of BNP is done only when diagnosis is unclear.
==Laboratory Findings==
==Laboratory Findings==
+
Plasma brain natriuretic peptide (BNP) or N-terminal pro b-type natriuretic peptide (NT-proBNP) can be used to diagnose heart failure when diagnosis is unclear. The markers have been found to have lower levels in diastolic dysfunction when compared with systolic dysfunction
{{cite journal| author=Maisel AS, McCord J, Nowak RM, Hollander JE, Wu AH, Duc P et al.| title=Bedside B-Type natriuretic peptide in the emergency diagnosis of heart failure with reduced or preserved ejection fraction. Results from the Breathing Not Properly Multinational Study. | journal=J Am Coll Cardiol | year= 2003 | volume= 41 | issue= 11 | pages= 2010-7 | pmid=12798574 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=12798574 }}
. Suggested partition values for diagnosis of DHF are BNP >100 pg/mL or NT-proBNP >300 pg/mL. In addition, BNP >100 pg/mL and NT-proBNP >300 pg/mL are independent predictors of adverse cardiovascular events in patients with heart failure with preserved left ventricular ejection fraction
{{cite journal| author=Grewal J, McKelvie RS, Persson H, Tait P, Carlsson J, Swedberg K et al.| title=Usefulness of N-terminal pro-brain natriuretic Peptide and brain natriuretic peptide to predict cardiovascular outcomes in patients with heart failure and preserved left ventricular ejection fraction. | journal=Am J Cardiol | year= 2008 | volume= 102 | issue= 6 | pages= 733-7 | pmid=18773998 | doi=10.1016/j.amjcard.2008.04.048 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=18773998 }}
.
+
+
==ACC/AHA 2009 Guidelines for the Diagnosis and Management of Chronic Heart Failure in the Adult: Initial Clinical Assessment Recommendation
Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG, Jessup M, Konstam MA, Mancini DM, Michl K, Oates JA, Rahko PS, Silver MA, Stevenson LW, Yancy CW, Antman EM, Smith SC Jr, Adams CD, Anderson JL, Faxon DP, Fuster V, Halperin JL, Hiratzka LF, Jacobs AK, Nishimura R, Ornato JP, Page RL, Riegel B; American College of Cardiology; American Heart Association Task Force on Practice Guidelines; American College of Chest Physicians; International Society for Heart and Lung Transplantation; Heart Rhythm Society. ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation. 2005 Sep 20; 112(12): e154-235. Epub 2005 Sep 13. PMID 16160202
Jessup M, Abraham WT, Casey DE, Feldman AM, Francis GS, Ganiats TG et al. (2009) [http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&retmode=ref&cmd=prlinks&id=19324967 2009 focused update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation.] ''Circulation'' 119 (14):1977-2016. [http://dx.doi.org/10.1161/CIRCULATIONAHA.109.192064 DOI:10.1161/CIRCULATIONAHA.109.192064] PMID: [http://pubmed.gov/19324967 19324967]
==
+
{|class="wikitable"
+
|-
+
| colspan="1" style="text-align:center; background:LightGreen"|[[ACC AHA guidelines classification scheme#Classification of Recommendations|Class I]]
+
+
|-
+
| bgcolor="LightGreen"|
"
'''1.''' Initial laboratory evaluation of patients presenting with [[heart failure]] should include [[complete blood count]], [[urinalysis]], [[Electrolytes|serum electrolytes]] (including [[calcium]] and [[magnesium]]), [[blood urea nitrogen]], [[serum creatinine]], [[fasting blood glucose]] ([[glycohemoglobin]]), [[lipid]] profile, [[liver function tests]], and [[thyroid-stimulating hormone]]. ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: C]])''
"
+
|}
+
{|class="wikitable"
+
|-
+
|colspan="1" style="text-align:center; background:LightCoral"| [[ACC AHA guidelines classification scheme#Classification of Recommendations|Class III]] (No Benefit)
+
|-
+
|bgcolor="LightCoral"|
"
'''1.''' Routine measurement of circulating levels of neurohormones (e.g., [[norepinephrine]] or [[endothelin]]) is not recommended for patients presenting with [[heart failure]]. ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: C]])''
"
+
|}
+
+
{|class="wikitable"
+
|-
+
| colspan="1" style="text-align:center; background:LemonChiffon"| [[ACC AHA guidelines classification scheme#Classification of Recommendations|Class IIa]]
+
|-
+
|bgcolor="LemonChiffon"|
"
'''1.''' Measurement of [[B-type natriuretic peptide]] ([[BNP]]) can be useful in the evaluation of patients presenting in the urgent care setting in whom the clinical diagnosis of [[heart failure]] is uncertain. Measurement of [[B-type natriuretic peptide|natriuretic peptides]] ([[BNP]] and NT-proBNP) can be useful in risk stratification.
{{cite journal |author=de Lemos JA, McGuire DK, Drazner MH |title=B-type natriuretic peptide in cardiovascular disease |journal=[[Lancet]] |volume=362 |issue=9380 |pages=316–22 |year=2003 |month=July |pmid=12892964 |doi=10.1016/S0140-6736(03)13976-1 |url=http://linkinghub.elsevier.com/retrieve/pii/S0140-6736(03)13976-1 |accessdate=2012-04-05}}
{{cite journal |author=Siebert U, Januzzi JL, Beinfeld MT, Cameron R, Gazelle GS |title=Cost-effectiveness of using N-terminal pro-brain natriuretic peptide to guide the diagnostic assessment and management of dyspneic patients in the emergency department |journal=[[The American Journal of Cardiology]] |volume=98 |issue=6 |pages=800–5 |year=2006 |month=September |pmid=16950189 |doi=10.1016/j.amjcard.2006.06.005 |url=http://linkinghub.elsevier.com/retrieve/pii/S0002-9149(06)01090-3 |accessdate=2012-04-05}}
{{cite journal |author=Gackowski A, Isnard R, Golmard JL, Pousset F, Carayon A, Montalescot G, Hulot JS, Thomas D, Piwowarska W, Komajda M |title=Comparison of echocardiography and plasma B-type natriuretic peptide for monitoring the response to treatment in acute heart failure |journal=[[European Heart Journal]] |volume=25 |issue=20 |pages=1788–96 |year=2004 |month=October |pmid=15474693 |doi=10.1016/j.ehj.2004.07.038 |url=http://eurheartj.oxfordjournals.org/cgi/pmidlookup?view=long&pmid=15474693 |accessdate=2012-04-05}}
{{cite journal |author=Bayés-Genís A, Santaló-Bel M, Zapico-Muñiz E, López L, Cotes C, Bellido J, Leta R, Casan P, Ordóñez-Llanos J |title=N-terminal probrain natriuretic peptide (NT-proBNP) in the emergency diagnosis and in-hospital monitoring of patients with dyspnoea and ventricular dysfunction |journal=[[European Journal of Heart Failure]] |volume=6 |issue=3 |pages=301–8 |year=2004 |month=March |pmid=14987580 |doi=10.1016/j.ejheart.2003.12.013 |url=http://eurjhf.oxfordjournals.org/cgi/pmidlookup?view=long&pmid=14987580 |accessdate=2012-04-05}}
{{cite journal |author=Dao Q, Krishnaswamy P, Kazanegra R, Harrison A, Amirnovin R, Lenert L, Clopton P, Alberto J, Hlavin P, Maisel AS |title=Utility of B-type natriuretic peptide in the diagnosis of congestive heart failure in an urgent-care setting |journal=[[Journal of the American College of Cardiology]] |volume=37 |issue=2 |pages=379–85 |year=2001 |month=February |pmid=11216950 |doi= |url=http://linkinghub.elsevier.com/retrieve/pii/S0735-1097(00)01156-6 |accessdate=2012-04-05}}
{{cite journal |author=Worster A, Balion CM, Hill SA, Santaguida P, Ismaila A, McKelvie R, Reichert SM, McQueen MJ, Booker L, Raina PS |title=Diagnostic accuracy of BNP and NT-proBNP in patients presenting to acute care settings with dyspnea: a systematic review |journal=[[Clinical Biochemistry]] |volume=41 |issue=4-5 |pages=250–9 |year=2008 |month=March |pmid=17915204 |doi=10.1016/j.clinbiochem.2007.08.008 |url=http://linkinghub.elsevier.com/retrieve/pii/S0009-9120(07)00303-7 |accessdate=2012-04-05}}
{{cite journal |author=O'Donoghue M, Kenney P, Oestreicher E, Anwaruddin S, Baggish AL, Krauser DG, Chen A, Tung R, Cameron R, Januzzi JL |title=Usefulness of aminoterminal pro-brain natriuretic peptide testing for the diagnostic and prognostic evaluation of dyspneic patients with diabetes mellitus seen in the emergency department (from the PRIDE Study) |journal=[[The American Journal of Cardiology]] |volume=100 |issue=9 |pages=1336–40 |year=2007 |month=November |pmid=17950786 |doi=10.1016/j.amjcard.2007.06.020 |url=http://linkinghub.elsevier.com/retrieve/pii/S0002-9149(07)01420-8 |accessdate=2012-04-05}}
{{cite journal |author=Silvers SM, Howell JM, Kosowsky JM, Rokos IC, Jagoda AS |title=Clinical policy: Critical issues in the evaluation and management of adult patients presenting to the emergency department with acute heart failure syndromes |journal=[[Annals of Emergency Medicine]] |volume=49 |issue=5 |pages=627–69 |year=2007 |month=May |pmid=17408803 |doi=10.1016/j.annemergmed.2006.10.024 |url=http://linkinghub.elsevier.com/retrieve/pii/S0196-0644(06)02461-9 |accessdate=2012-04-05}}
''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: A]])''
"
+
|-
+
|bgcolor="LemonChiffon"|
"
'''2.''' Screening for [[hemochromatosis]], [[Cheyne-Stokes respiration#Association with Congestive Heart Failure (CHF)|sleep-disturbed breathing]], or [[HIV|human immunodeficiency virus]] is reasonable in selected patients who present with [[heart failure]]. ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: C]])''
"
+
|-
+
|bgcolor="LemonChiffon"|
"
'''3.''' Diagnostic tests for rheumatologic diseases, [[amyloidosis]], or [[pheochromocytoma]] are reasonable in patients presenting with [[heart failure]] in whom there is a clinical suspicion of these diseases. ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: C]])''
"
+
|}
+
+
==ACC/AHA 2009 Guidelines for the Diagnosis and Management of Chronic Heart Failure in the Adult: Serial Clinical Assessment Recommendation
Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG, Jessup M, Konstam MA, Mancini DM, Michl K, Oates JA, Rahko PS, Silver MA, Stevenson LW, Yancy CW, Antman EM, Smith SC Jr, Adams CD, Anderson JL, Faxon DP, Fuster V, Halperin JL, Hiratzka LF, Jacobs AK, Nishimura R, Ornato JP, Page RL, Riegel B; American College of Cardiology; American Heart Association Task Force on Practice Guidelines; American College of Chest Physicians; International Society for Heart and Lung Transplantation; Heart Rhythm Society. ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation. 2005 Sep 20; 112(12): e154-235. Epub 2005 Sep 13. PMID 16160202
Jessup M, Abraham WT, Casey DE, Feldman AM, Francis GS, Ganiats TG et al. (2009) [http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&retmode=ref&cmd=prlinks&id=19324967 2009 focused update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation.] ''Circulation'' 119 (14):1977-2016. [http://dx.doi.org/10.1161/CIRCULATIONAHA.109.192064 DOI:10.1161/CIRCULATIONAHA.109.192064] PMID: [http://pubmed.gov/19324967 19324967]
(DO NOT EDIT)==
+
+
{|class="wikitable"
+
|-
+
| colspan="1" style="text-align:center; background:LemonChiffon"| [[ACC AHA guidelines classification scheme#Classification of Recommendations|Class IIb]]
+
+
|-
+
|bgcolor="LemonChiffon"|
"
'''1.''' The value of serial measurements of [[BNP]] to guide therapy for patients with [[heart failure]] is not well established. ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: C]])''
"
+
|}
==References==
==References==